Skip to main content

Table 2 Mean QLQ-PR25 values of the brachytherapy group after 51 months compared to the long-term follow-up after 141 months. There are two columns for the first follow-up, the first one shows only the (4.3-year) results for patients alive after long-term follow-up; the second shows the results for all patients

From: Quality of life after low-dose rate-brachytherapy for prostate carcinoma – long-term results and literature review on QLQ-C30 and QLQ-PR25 results in published brachytherapy series

Item or scale Follow-up 4.3 years; only long-term survivors shown Follow-up 4.3 years all patients shown Follow-up 11.7 years
Urinary-related symptoms 25.6 (SD = 19.1; n = 79) 29.7 (SD = 23.7; n = 240) 24.3 (SD = 21.8; n = 79)
Bowel-related symptoms 7.3 (SD = 14.1; n = 74) 8.2 (SD = 13.4; n = 223) 8.5 (SD = 12.3; n = 73)
Hormone treatment-related symptoms 11.2 (SD = 11.6; n = 74) 15.5 (SD = 16.1; n = 230) 14.7 (SD = 16.0; n = 76)
Sexual activity 51.1 (SD = 29.1; n = 76) 45.5 (SD = 32.4; n = 234) 40.5 (SD = 31.2; n = 74)
Sexual function 61.6 (SD = 19.3; n = 58) 57.5 (SD = 23.7; n = 154) 64.5 (SD = 23.1; n = 34)
Bother due to use of an incontinence aid 50 (SD = 45.9; n = 6) 43.4 (SD = 38.6; n = 33) 66.7 (SD = 36; n = 13)
Incontinencea 7.5% 12.9% 16.3%
  1. aEstimated by percentage of patients wearing an incontinence aid